Home › Trials › NCT05259605

Observational assessment of treatment outcomes for patients with primary brain tumors

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification

European Organisation for Research and Treatment of Cancer - EORTC · NCT05259605

This study looks at how well treatments work for people with rare primary brain tumors using new classification guidelines to see if they help doctors group patients better.

Quick facts

Study typeObservational
Enrollment1650 (estimated)
Ages18 Years and up
SexAll
SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC (network)
Locations42 sites (Innsbruck and 41 other locations)
Trial IDNCT05259605 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the treatment and outcomes of patients diagnosed with rare primary brain tumors using the new 2021 WHO classification and cIMPACT-NOW recommendations. It seeks to determine if the updated classification leads to more consistent patient groupings compared to the previous 2016 classification. By collecting data on treatment experiences and outcomes, the study will help establish provisional guidelines for managing these newly defined tumor entities. The focus is on newly diagnosed or recurrent tumors, with an emphasis on those considered rare.

Who should consider this trial

Good fit: Ideal candidates include individuals with newly diagnosed or recurrent primary brain tumors, particularly rare types.

Not a fit: Patients with common brain tumors or those without available archival tumor tissue may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide clearer treatment guidelines and improve outcomes for patients with rare primary brain tumors.

How similar studies have performed: Other studies have shown success in using updated classifications to improve treatment outcomes, suggesting this approach may be beneficial.

Eligibility criteria

Show full inclusion / exclusion criteria 
* Age ≥ legal age of consent
* Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest
* Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exception: only tissue from first surgery is allowed for Cohort 16.
* Available MRI/CT scans from primary brain tumour at initial diagnosis
* Patient's consent

Deceased patient:

The clinical data and/or biological material and/or CT/MRI/PET images can be accessed and used if at least one of the following three conditions is met:

* The patient agreed beforehand in his/her lifetime to a further use of his/her data and/or biological material and/or CT/MRI/PET images, or,
* There is consent of a relative to use data and/or biological material and/or CT/MRI/PET images of the deceased patient, or,
* There is a reference to a corresponding legal declaration covering the exemption in case of the impossibility or disproportion of getting access to an informed consent (e.g., causing strain on relatives of deceased patients).

Additionally, in all cases the following three points need to be fulfilled:

* No documentation of previous objection of the patient to the (re-)use of their data, biological material, CT/MR/PET images for research purposes
* A notification to an ethics committee for the re-use of these data, biological material and CT/MRI/PET images
* Any other national requirements are fulfilled, if applicable

Where this trial is running

Innsbruck and 41 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors, Germ Cell Tumor, Tumor of the Sellar Region, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.